TRIANA Biomedicines

About TRIANA Biomedicines

TRIANA Biomedicines is a venture-backed biopharmaceutical company focused on discovering and developing novel therapeutics using molecular glues to treat diseases. Their technology promotes protein interactions to alter disease target proteins, with an initial focus on targeted protein degradation (TPD) to address undruggable targets and develop groundbreaking cancer medicines.

Products & Services

Molecular Glues:Innovative compounds that promote protein-protein interactions to alter the fate or function of disease target proteins, including activating protein degradation machinery to destroy disease targets, particularly in cancer treatment.

Specialties

Molecular Glue Discovery Targeted Protein Degradation (TPD) Cancer Therapeutics Drugging Undruggable Targets

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 120000000 MR: - FA: $120 million FAN: 120000000	D: 2025-12-03 FD: 2025-12-03	11 investors

Series B Latest

2025-12-03

$120.0M

11 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jim Ellis

P

Patrick Trojer

President & Chief Executive Officer

C

Caroline Germa

Chief Medical Officer

V

Vito Palombella

Chief Scientific Officer

B

Brenda Sousa

Acting Head of Human Resources

K

Karen Valentine

Acting General Counsel

View 25 more team members with Pro

Unlock Full Team Directory

Recent News